Reindustrialization: Core to Our DNA
SPENGLER MEDICAL is fully committed to the reindustrialization movement. In a medical sector long characterized by offshoring, SPENGLER MEDICAL has chosen the opposite path — production rooted in Europe, serving healthcare and caregivers, and meeting the quality standards expected by the market.
With its two production sites located in France (Castelculier and Saint-Léonard-de-Noblat), the company actively contributes to the revitalization of the French industrial fabric: maintaining and creating skilled jobs, local mastery of expertise, and reducing dependence on foreign supplies.
Located in Germany, the Blaubeuren site complements SPENGLER MEDICAL’s European industrial network. It concentrates cutting-edge technical expertise and contributes to controlling the entire production chain, in compliance with the quality requirements that define the group’s reputation. It is also in Blaubeuren that SPENGLER MEDICAL has relocated its otoscope manufacturing.
R&D Committed to Medical Innovation
Producing in Europe and innovating for users: this is the dual ambition that structures SPENGLER MEDICAL’s industrial vision.
Dedicated teams work on designing tomorrow’s medical devices, closely involving healthcare professionals at every stage of development.
This is why SPENGLER MEDICAL closely involves healthcare professionals in its development work, to deeply understand their practices, constraints, and expectations, and to make these the foundation of every innovation.
Cardiology Diagnostics
High-performance diagnostic tools to support cardiologists in their daily practice.
Patient Warming
Reliable warming solutions adapted to the constraints of demanding clinical environments.
Orthopedic Surgery Operating Room
Specialized equipment designed to meet the demands of the operating room in orthopedic surgery.
SPENGLER MEDICAL in Figures
Behind each figure are qualified teams, multiple production sites, and a clear ambition: to make SPENGLER MEDICAL a major player in medical manufacturing.
3
100% European production sites
4%
Of Revenue Invested in R&D
3
Patented Technologies
10
New Products in 2025/2026